GlassScriptPhysician profile
Ingrid Mcfadden
NPI 1942752704
$2,004.63
in general payments reported to CMS, 2019-2025
14 companies · $595 in 2025
The $595 reported for 2025 was more than what 89% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $112 · 2023: $631 · 2024: $308 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $719.64 | 2023-2025 | |
| Abbvie INC. | $345.95 | 2021-2025 | |
| Exeltis, USA INC. | $268.74 | 2021-2025 | Slynd |
| Aspira Women'S Health INC | $255.23 | 2021 | |
| Astellas Pharma US INC | $133.74 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $84.17 | 2023 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $47.72 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $43.25 | 2023-2025 | Gardasil 9, Gardasil |
| Hologic Sales and Service, LLC | $20.42 | 2024 | Aptima |
| Mylan Pharmaceuticals INC. | $19.52 | 2021 | |
| Evofem Biosciences, INC. | $19.24 | 2023 | Phexxi |
| Millicent US INC | $18.73 | 2025 | Femlyv, Intrarosa |
| Renovia INC | $14.35 | 2021 | |
| Exact Sciences Corporation | $13.93 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.